Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Clin Genitourin Cancer. 2012 Oct 9;11(2):149–154. doi: 10.1016/j.clgc.2012.09.006

Table 2.

Systemic therapy regimens of patients who completed the survey (n=28). Of note, 8 patients (28.5%) received more than 3 lines of systemic therapy

Systemic Therapy n (%)
1st Line Therapy (n=28)
 Immunotherapy
  Interferon 2 (7.1%)
  Interleukin-2 1 (3.5%)
 VEGF-Directed
  Bevacizumab 2 (7.1%)
  Cediranib 1 (3.5%)
  Pazopanib 2 (7.1%)
  Sorafenib 1 (3.5%)
  Sunitinib 13 (46.4%)
 mTOR-Directed
  Everolimus 1 (3.5%)
  Temsirolimus 1 (3.5%)
2nd Line Therapy (n=25)
 Immunotherapy
  Interferon 1 (4.0%)
  Interleukin-2 1 (4.0%)
 VEGF-Directed
  Cabozantinib 1 (4.0%)
  Sorafenib 2 (8.0%)
  Sunitinib 6 (24.0%)
 mTOR-Directed
  Everolimus 8 (32.0%)
  Temsirolimus 4 (16.0%)
 Other
  CRLX101 1 (4.0%)
3rd Line Therapy (n=18)
 VEGF-Directed
  Pazopanib 8 (44.0%)
  Sorafenib 5 (27.8%)
  Sunitinib 1 (5.6%)
 mTOR-Directed
  Everolimus 2 (11.1%)
  Temsirolimus 1 (5.6%)